Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Celcuity Inc.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Celcuity today and set a price target of $94.00. Ramakanth covers the He...

H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and BioNTech SE (B...

Market Cap	$5.59B	P/E Ratio	N/A
52W High	$120.32	52W Low	$7.58
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	97.3%
Overall Score	43	Value Score	40
Quality Score	31	Technical Score	60

EPS Current Est	$-3.97	EPS Next Est	$-0.69
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CELC	$117.24	-5.94%	473.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CELC	$117.24	-5.9%	473.17K
3
4
5
6

CELC

CELC

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Celcuity Inc. Data in Excel

Get Celcuity Inc. Data in Excel